ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Nivalis Therapeutics, Inc." (NVLS) Report Updated: Dec 07, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Nivalis Therapeutics, Inc." (NVLS)

Rating: Strong Sell Volatility: Aggressive
Total Grade: F Industry: Biotechnology
Competitors: CLCD,EXEL,ALBO,XNCR

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: F down downgrade
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Nivalis Therapeutics, Inc."© quotemedia

Company Profile

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase II clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.